清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Comparing the outcome of doublet therapy (gemcitabine and cisplatin) with triplet therapy (gemcitabine, cisplatin and nab paclitaxel) in locally advanced or metastatic gall bladder carcinoma patients: An open-label randomized control trial.

吉西他滨 医学 养生 肿瘤科 内科学 顺铂 膀胱癌 随机对照试验 化疗 癌症
作者
C. Khatri,Priya Das,Jayanta Patowary
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:40 (4_suppl): TPS497-TPS497
标识
DOI:10.1200/jco.2022.40.4_suppl.tps497
摘要

TPS497 Background: There are various studies evaluating the role of dual agent chemotherapy like gemcitabine and cisplatin in locally advanced or metastatic gall bladder cancer (1). This has been the standard of treatment up till now. Also there has been a single arm phase II trial of gemcitabine, cisplatin and nab-paclitaxel (triplet therapy) by Shroff et al (2) reporting an impressive data with RR (response rate) of 45 %, median PFS (progression free survival) of 11.8 months (5% CI; 6.0-15.6) and median OS (overall survival) was 19.2 months. This data was promising when compared to historical data of dual agents like gemcitabine and cisplatin. So it would be informative to conduct an RCT comparing doublet chemotherapy in locally advanced or metastatic GBC with triplet regimen chemotherapy. Methods: It is an open label randomized control study conducted in Indraprastha Apollo hospital New Delhi, India in newly diagnosed locally advanced or metastatic gall bladder cancer patients proven histologically and on imaging. The sample size calculated using the appropriate formula is, 27 in each arm that is total of 54 patients, but 60 patients will be enrolled in the study keeping in view 10% drop out rate. For simple randomization, we will use online computer generated random number table and then patients will be assigned in two groups, arms A and B. Arm A receiving two drugs gemcitabine 1,000mg/m2 i.v and cisplatin 25mg/m2 i.v on Day 1 and Day 8 of 21-day cycle and arm B receiving three drugs gemcitabine, 1,000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and 8 of 21-day cycle. Primary end point was response rates based on radiological response as per RECIST or PRECIST. Secondary end points were to determine median progression free survival and median overall survival and to evaluate the toxicities according to NCI-CTC v 4.0.Then response [on basis of RECIST or PRECIST criteria] will be seen after 3 and 6 cycles of chemotherapy are completed and at follow up of every 6 months for 2 years period for assessment of primary and secondary end points of the study. Statistical analysis for correlation between clinical and laboratory features and treatment outcomes will be done using the SPSS software. Till now we have enrolled 1 patient in each arm. CTRI/2021/09/036362. References: Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine,Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial JAMA Oncol 2019. Clinical trial information: CTRI/2021/09/036362.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_LN32Mn完成签到,获得积分10
8秒前
静_完成签到 ,获得积分10
14秒前
盛事不朽完成签到 ,获得积分10
29秒前
玩命的寄翠完成签到 ,获得积分10
32秒前
首席医官完成签到,获得积分10
48秒前
在水一方完成签到 ,获得积分0
51秒前
乌日完成签到 ,获得积分10
51秒前
56秒前
酷炫越泽发布了新的文献求助10
59秒前
隐形曼青应助ww采纳,获得10
1分钟前
糊涂的青烟完成签到 ,获得积分10
1分钟前
乐正怡完成签到 ,获得积分0
1分钟前
ww完成签到,获得积分10
1分钟前
666完成签到 ,获得积分10
1分钟前
xzl完成签到 ,获得积分10
2分钟前
tx完成签到,获得积分10
2分钟前
路在脚下完成签到 ,获得积分10
2分钟前
不爱吃西葫芦完成签到 ,获得积分10
2分钟前
天天快乐应助橙100采纳,获得10
2分钟前
vikey完成签到 ,获得积分10
2分钟前
不回首完成签到 ,获得积分10
2分钟前
简洁完成签到 ,获得积分10
2分钟前
萧子完成签到 ,获得积分10
2分钟前
不打扰完成签到 ,获得积分10
2分钟前
ycd完成签到,获得积分10
3分钟前
古炮完成签到 ,获得积分10
3分钟前
白桃完成签到 ,获得积分10
3分钟前
3分钟前
科研通AI2S应助科研通管家采纳,获得30
3分钟前
3分钟前
橙100发布了新的文献求助10
3分钟前
cadcae完成签到,获得积分10
3分钟前
沧海一粟米完成签到 ,获得积分10
3分钟前
chichenglin完成签到 ,获得积分10
4分钟前
宋芽芽u完成签到 ,获得积分10
4分钟前
荔枝小妹完成签到 ,获得积分10
4分钟前
领导范儿应助执着易形采纳,获得30
4分钟前
拼搏山槐完成签到 ,获得积分10
4分钟前
光亮秋天完成签到 ,获得积分10
4分钟前
称心的海蓝完成签到 ,获得积分10
4分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546022
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600229
捐赠科研通 1896383
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557